Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

These are diseases in which the immune system targets and attacks normal thyroid cells. There are three common antibodies associated with autoimmune thyroid disease: These blood tests measure the ...

Legend Biotech faces a 60% stock drop amid safety, supply issues, and competition for its CAR-T therapy, Carvykti. See here for an analysis of LEGN stock.

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

The past decade in oncology has been marked by the rise of immunotherapy, which leverages the immune system to attack tumors. For many solid tumors, immune checkpoint inhibitors have supplanted ...

Patients are really doing quite well on the drug. Approximately how many patients who have been previously treated with the approved antibody-drug conjugate for HER2-mutated NSCLC are now in need ...

SENTI-202, an off-the-shelf, logic-gated, CAR natural killer cell therapy drove complete remission of pretreated blood cancers in a first-in-human trial, according to results presented by Stephen ...

An ELISA test is a blood test that looks for antibodies in your bloodstream. When certain antibodies are present, it’s a sign your immune system is trying to fight off a disease. Here’s how ...

The FDA has approved Akeso’s penpulimab-kcqx, a PD-1 monoclonal antibody, for two indications treating nasopharyngeal carcinoma (NPC). The drug is now indicated in combination with chemotherapy as a ...